PF-Atlas › Clinical Trials › NCT00332215
A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
Inhaled Sodium Pyruvate · Phase 1
Registry ID
NCT00332215
Phase
Phase 1
Status
Terminated
Drug / intervention
Inhaled Sodium Pyruvate
Sponsor
University of Minnesota
Start
2006-02
About this trial
Inhaled Sodium Pyruvate is evaluated in NCT00332215, a Phase 1 idiopathic pulmonary fibrosis study sponsored by University of Minnesota. Current status: Terminated.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00332215 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.